2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents

The complex etiology of Alzheimer’s disease prompts scientists to develop multi-target strategies to combat causes and symptoms. In line with this modern paradigm and as a follow-up to our previous studies, we designed and synthesized a focused collection of new 2-arylbenzofurans and evaluated their biological properties towards specific targets involved in AD, namely human AChE and human BuChE, and Abeta fibril formation. Selected compounds were also tested for their ability to inhibit Abeta neurotoxicity in terms of neuronal viability loss, and to prevent Abeta peptide-binding to cell membrane and intracellular ROS formation. The different modifications introduced in the structure of our lead compound led to an increase in activity towards one or more of the selected targets: the anticholinesterase activity of some compounds was found to be significantly higher than previously obtained related molecules, and the compounds also proved to possess Abeta anti-aggregating properties and neuroprotective effects. The most interesting multi-target compounds were 18 and 1. Interestingly, 1 also showed good selectivity and moderate affinity for CB1 receptor, opening new perspectives in the field of research on AD, since cannabinoid ligands have been widely reported to have neuroprotective properties.